Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries with an annual incidence of 3-5 cases per 100 000. CLL is characterized by the clonal proliferation and accumulation of mature CD5 þ B lymphocytes in the blood, bone marrow, lymph nodes and spleen. The median age of patients at diagnosis is 65 years, with only 10-15 percent of those diagnosed under 50 years of age. Although it may have an indolent clinical course with survival in some cases up to 20 years after diagnosis, once the disease progresses, death is almost unavoidable (Rozman and Montserrat, 1995; Byrd et al., 2004) . Although a number of treatment modalities, including alkylator therapy, purine analogs, monoclonal antibodies and their combinations are available for CLL, none are curative, making identification of new treatments quite relevant. Alemtuzumab is one such therapy. Alemtuzumab is an unconjugated, humanized IgG1 kappa monoclonal antibody which targets the CD52 antigen (Flynn and Byrd, 2000; Frampton and Wagstaff, 2003; Robak, 2005) . This review will encompass both the biologic characteristics of the CD52 target and the available clinical data regarding the use of alemtuzumab for treatment of CLL.
The CD52 antigen
The CD52 antigen is a glycoprotein with a short sequence of only 12 amino acids and a molecular weight of 21-28 kDa. There is a large complex carbohydrate attached to Asparagine-3 which terminates with negatively-charged sialic acid residues; this complex is 2-3 times larger than the peptide core (Hale et al., 1990; Xia et al., 1993a) . At the C-terminus, a glycosylphosphatidylinositol (GPI) lipid anchor attaches the molecule to the outer layer of the cell membrane (Hale, 2001) . CD52 is highly expressed on membrane lipid rafts of all B and T lymphocytes (Rossmann et al., 2001) at most stages of differentiation (except plasma cells), as well as on monocytes, macrophages, eosinophils, natural killer cells and dendritic cells (Elsner et al., 1996; Buggins et al., 2002; Ratzinger et al., 2003) . Radioisotopic methods have estimated that peripheral blood lymphocytes have approximately 500 000 CD52 molecules per cell (Ginaldi et al., 1998) , comprising 5% of the cell surface. The antigen is also found in the male reproductive tract, where it is strongly expressed on epithelial cells lining the epididymis, vas deferens and seminal vesicles (Hale et al., 1993) . It is shed into seminal plasma, from where it can be transferred to other cells, particularly spermatozoa. Hematopoietic stem cells, erythrocytes and platelets do not express this antigen and are thus spared a direct antibody effect (Gilleece and Dexter, 1993) .
The physiologic functions of CD52 remain to be clarified, but it may mediate a variety of biological effects such as signal transduction, promotion of cell-cell adhesion and protection of the cell from environmental insult. A recent paper suggested that CD52 may contribute to the activation of T-regulatory cells (Watanabe et al., 2006) . The CD52 antigen is also expressed on subsets of tumor cells, particularly T-cell prolymphocytic leukemia followed by CLL, hairy cell leukemia, non-Hodgkin lymphomas (NHL), and acute lymphoblastic leukemia (Ginaldi et al., 1998; Cheson, 2006) .
Alemtuzumab mechanism of action
Despite the frequent use of alemtuzumab in clinical trials, detailed mechanistic studies to elucidate specific pathways of cell killing have been hampered by the lack of cell lines expressing CD52. Thus, the mechanism of action of alemtuzumab remains to be clarified. The epitope recognized by alemtuzumab consists of the C-terminal peptide and a portion of the GPI anchor. As such, the alemtuzumab/CD52 complex approximates the cell membrane, favoring the deposition of activated complement molecules and facilitating the necessary contacts for cell-mediated killing (Xia et al., 1993b) . Alemtuzumab can act through immunological mechanisms, such as complement-mediated (CDC) (Xia et al., 1993b; Golay et al., 2004; Zent et al., 2004) and/or antibody-dependent cellular cytotoxicity (ADCC) by virtue of its IgG Fc region (Hale et al., 1983 (Hale et al., , 1985 Crowe et al., 1992) . Clynes et al. (2000) showed that the inhibitory Fcg receptor (Fcg R) IIB is a potent regulator of ADCC in vivo, modulating the activity of Fcg RIII (activation receptor) on effector cells. The authors demonstrated that knocking out the Fcg loci completely abrogated the response to the anti-CD20 monoclonal antibody rituximab in a xenograft model of human NHL, whereas knocking out the inhibitory Fcg RIIb enhanced the response to rituximab in the same xenograft model. Similarly, Zhang et al. (2006) reported that engagement of Fcg R on effector cells is also the main mechanism of the in vivo ADCC responses mediated by alemtuzumab against HTLV-1-expressing T cells that are CD52 positive. To date, the importance of ADCC in alemtuzumab for B-cell diseases has not been described. While it has been demonstrated that the high-affinity Fcg RIIIA genotype (Cartron et al., 2002) correlates with clinical and molecular response to rituximab in patients with follicular NHL, our group (Lin et al., 2005b) has not confirmed this response to alemtuzumab in CLL.
Two recent studies have shown that alemtuzumab may also induce enhanced apoptosis in vitro, alone or in combination with a cross-linking anti-Fc antibody, on primary CLL cells in the absence of complement or immune effector cells, leading to rapid cell death in vitro through a nonclassic caspase-independent pathway (Stanglmaier et al., 2004; Mone et al., 2006) . Mone et al. (2006) also proposed that crosslinking of CD52 by virtue of its GPI linkage could initiate CLL cell death through a membrane raft-dependent mechanism. In fact, the authors hypothesized that the observed aggregation of glycolipid-enriched membrane domains in the CLL plasma membrane surface induced by alemtuzumab could mediate subsequent formation of signaling complexes and induction of cell death (Deans et al., 2002; Garcia et al., 2003) . There is also evidence to suggest that alemtuzumab may trigger caspase-dependent cell death (Nuckel et al., 2005; Smolewski et al., 2005) . Direct cytotoxicity has also been reported in the B-lymphoid cell lines Wien 133 (Rowan et al., 1998) and Ramos (Stanglmaier et al., 2004) . Contrasting with this, another study has shown that alemtuzumab alone did not induce apoptosis in serum-free medium (Zent et al., 2004) . The in vivo relevance of such serum-free experiments is uncertain.
Recently, Watanabe et al. (2006) proposed a novel function of the CD52 antigen as a potential costimulatory molecule for T cells, when they showed that CD52 stimulation of CD4 þ T cells by alemtuzumab contributed to the disruption of T-cell transmigration as well as to the induction of regulatory T cells. CD4 þ regulatory T cells are hyporesponsive cells that belong to a specialized population of lymphocytes with immunosuppressive properties. It has been demonstrated that these cells are able to suppress the polyclonal responses of both CD4 þ and CD8 þ T cells when polyclonal or allogeneic stimulation is applied. These results suggest that activation of CD4 þ regulatory T cells by alemtuzumab combined with lymphocyte depletion may contribute to the immunosuppressive effects of this drug.
Dosage and schedule of administration of alemtuzumab in CLL
The dosing schedule of alemtuzumab was developed empirically using primarily clinical response as a surrogate endpoint in initial phase I studies. Further schedule optimization has been limited by a paucity of pharmacologic assays due to the difficulty of generating high-affinity anti-alemtuzumab antibodies. Although a flow cytometric cell surface antigen pharmacologic assay exists, it is quite expensive and laborious. To this day, the optimal dose and schedule of alemtuzumab remain to be defined. It has been estimated that approximately 125 mg of alemtuzumab are required to saturate all of the CD52 binding sites in a healthy adult, considering that an adult has an estimated 10 12 lymphocytes and each lymphocyte has approximately 500 000 binding sites for alemtuzumab (Ginaldi et al., 1998) . CLL cells express similar amounts of CD52 antigen as normal lymphocytes, but their total number may be 10 times greater. Therefore, more than 1 g of alemtuzumab could be required to saturate all CD52 receptors in some CLL patients.
The intravenous (i.v.) dosing schedule currently used as the standard regimen for alemtuzumab therapy is comprised of a 2-h i.v. infusion at a starting dose of 3 mg day 1, 10 mg day 2 and 30 mg three times weekly for a total of 8-12 weeks, once the infusion-related side effects are tolerable. Given that the majority of patients treated with i.v. alemtuzumab experience infusional toxicity combined with the observation that subcutaneous (SQ) alemtuzumab in patients with rheumatoid arthritis had biological activity with diminished infusion-related events (Isaacs et al., 1992) , interest in s.c. administration has increased. Indeed, recent reports have demonstrated that s.c. alemtuzumab administration achieves blood levels equivalent to those seen following i.v. administration, even if accumulation of alemtuzumab in the peripheral blood takes significantly longer (on average, 6 weeks longer to reach the same concentration obtained with i.v. administration) (Hale et al., 2004) . Thus, SQ dosing is becoming the favored route of administration in order to decrease toxicity and to facilitate outpatient treatment of CLL patients.
Alemtuzumab in previously treated CLL
The effectiveness of alemtuzumab in patients with previously treated CLL has been reported in several studies. Osterborg et al. (1997) reported a phase II trial of 29 previously treated CLL patients which demonstrated an overall response rate (ORR) of 42%, with one complete remission (CR) (4% of patients). The median duration of response was 12 months in this study. Keating et al. (2002) investigated the efficacy and safety of alemtuzumab therapy in 93 patients with relapsed or refractory CLL whose disease was previously treated with alkyaltor therapy and refractory to fludarabine. In this study, the ORR was 33%, including two patients who achieved a CR (2%). The median duration of response was 8.7 months and median overall survival (OS) was 16 months, with a median survival for responders of 32 months. Responses in this study were infrequent among patients with large lymph nodes (>5 cm) or poor performance status (ECOG performance status X2). The results were confirmed by other phase II trials (Ferrajoli et al., 2003) .
In an attempt to reduce initial infusion-related toxicity seen with i.v. alemtuzumab, Bowen et al. (1997) investigated the efficacy and tolerability of SQ alemtuzumab for 6-12 weeks in six fludarabine-refractory CLL patients. The ORR was 60%, but no complete responses were observed. The median duration of response was not reported. The median OS was 11 months. A recent German CLL Study Group study (Stilgenbauer and Dohner, 2002 ) demonstrated similar efficacy of alemtuzumab (30 mg SQ) three times weekly for 12 weeks when compared to historical data where the same total dose of alemtuzumab was administered i.v. In the first 50 patients enrolled with fludarabinerefractory CLL, injection-related toxicity was minimal and the ORR was 36% (CR 2%, partial remission (PR) 34%), with a median progression free survival (PFS) of 9.7 months.
Alemtuzumab as initial therapy for symptomatic CLL
A pilot study of nine patients with advanced CLL using alemtuzumab as first-line therapy demonstrated the feasibility of this agent in untreated patients (Osterborg et al., 1996) . On the basis of these findings, Lundin et al. (2002) treated 41 CLL patients with SQ alemtuzumab as first-line therapy for up to 18 weeks, with an observed ORR of 87% including seven patients (19%) with a CR. Although CLL cells were rapidly cleared from peripheral blood, alemtuzumab had to be continued for 18 weeks to achieve the maximum response in the bone marrow. The median time to treatment failure had not been reached at the time of publication (18 þ months, range 7-44 þ ). The treatment was generally well tolerated, with adverse events mainly comprised of local injection site reactions, with no episodes of febrile neutropenia or major bacterial infections. Cytomegalovirus (CMV) reactivation occurred in 10% of patients.
On the basis of the findings of Lundin et al. (2002) a prospective international randomized phase III trial was performed comparing the efficacy and safety of alemtuzumab with chlorambucil as first-line therapy in patients with progressive CLL. Patients were randomized to receive alemtuzumab (30 mg i.v.) three times weekly for a maximum of 12 weeks or chlorambucil 40 mg/m 2 orally every 28 days for up to a maximum of 12 cycles. The accrual was completed in July 2004 with 297 patients enrolled. The preliminary results of this trial (Hillmen et al., 2006) showed an ORR rate of 83.2% in the alemtuzumab arm as compared to 56% in chlorambucil arm. Alemtuzumab resulted in a 24% CR rate, whereas there were only 2% CRs in those receiving chlormabucil. The alemtuzumab arm had slightly more infectious complications, predominately due to CMV viremia (46%) and infection (11%) in alemtuzumabtreated patients as compared to CMV viremia (3%) only in the chlorambucil arm. Responses in high-risk del(17p13.1) patients were more frequent among those randomized to alemtuzumab compared with chlorambucil. These findings corroborate those of others (Lozanski et al., 2004) who found that alemtuzumab may be effective in high-risk CLL as measured by response. Although alemtuzumab improved ORR and CR rates compared with chlorambucil, longer follow-up is needed to evaluate PFS and OS. Similarly, it will be important to assess if improved ORR in patients with 2 ) and i.v. alemtuzumab. Dose escalation of alemtuzumab was performed on consecutive days from 3 to 10 to 30 mg. The combination was administered for three consecutive days every 28 days for a total of six cycles (four cycles in the first 14 patients). The ORR was 83%, with 11 patients achieving a CR (30%) and 19 patients achieving a PR (53%). The median OS was 35.6 months for all patients, with a time to progression of 22 months in patients who achieved a CR and 13 months for patients who achieved a PR. The treatment was well tolerated with acceptable infectious morbidity. Based upon these results, a phase III study comparing fludarabine to fludarabine plus alemtuzumab is currently underway in Europe.
Alemtuzumab and rituximab
Alemtuzumab and rituximab are monoclonal antibodies that target different antigens on CLL cells, and outside of infusion-related events have nonoverlapping toxicities. Faderl et al. (2003) evaluated the safety and efficacy of rituximab combined with alemtuzumab in 32 patients with CLL. Patients received rituximab (375 mg/m 2 ) weekly for 4 weeks and i.v. alemtuzumab with the escalating dose of 3 mg, 10 mg and 30 mg the first week followed by a dose of 30 mg on days 3 and 5 of weeks 2, 3 and 4. The ORR was 63% in the CLL patients, with only two (6%) achieving a CR. Almost all patients experienced a complete resolution of circulating CLL cells, but only 36% attained morphologic remissions in the bone marrow, possibly as a result of the short duration of therapy. The median time to progression was 6 months and the median OS was 11 months. The combination was well tolerated, but CMV antigenemia was observed in 27% of patients (13 of the 48 patients), 15% of which were associated with infection that required therapy. This study showed that the combination of rituximab with alemtuzumab is feasible and safe, however, the results also indicate that although combination of these two monoclonal antibodies may initially yield higher ORR, remission duration may be short. Future efforts are examining maintenance strategies using dual antibody therapy.
Alemtuzumab with fludarabine, cyclophosphamide and rituximab
Alemtuzumab has been combined with fludarabine, cyclophosphamide and rituximab with the goal of improving CRs and eliminating minimal residual disease (MRD). Wierda et al. (2004) reported the preliminary results of a phase II trial in which 31 patients with pretreated CLL were treated with cyclophosphamide (250 mg/m 2 day 3-5), fludarabine (25 mg/m 2 day 3-5, i.v.) alemtuzumab (30 mg day 1, 3, 5) and rituximab (500 mg/m 2 day 2), every 28 days for six cycles. Twentyone patients were evaluable for response and after a median number of three cycles (range 1-6) the ORR rate was 52%, with three patients achieving a CR (14%) and eight patients achieving a PR (38%). CMV reactivation was noted in five of 21 patients. Based upon these results, a larger phase II study in patients with high risk, previously untreated symptomatic CLL has been initiated at the MD Anderson Cancer Center.
Alemtuzumab consolidation
Alemtuzumab has been shown to work best against blood, spleen and marrow CLL but is less effective against lymph node disease. Dyer et al. (1997) initially demonstrated the feasibility of administering alemtuzumab as consolidation to eliminate MRD. A study by the CALGB was designed to confirm these results (Rai et al., 2002) . Fifty-six previously untreated, symptomatic CLL patients were treated with fludarabine for four courses of therapy followed by a 2 month observation period and then i.v. alemtuzumab (30 mg) three times a week for six consecutive weeks. Of 36 evaluable patients, there were 15 CRs (42%) and 18 PRs (50%) with an ORR of 92%. On the basis of the response rates in this study, the CALGB performed a phase II study of fludarabine and rituximab followed by consolidation alemtuzumab. The results of this study are greatly anticipated.
A second study reported by O'Brien et al. The German CLL Study Group (Wendtner et al., 2004) reported the results of a phase III trial where patients responding to fludarabine alone or in combination with cyclophosphamide were randomized to receive i.v. alemtuzumab 30 mg three times weekly for a maximum of 12 weeks, or observation. Of 21 evaluable patients, 11 were randomized to receive alemtuzumab. This study was prematurely closed because of severe infections in seven of 11 patients in the alemtuzumab arm, whereas only two minor infections occurred in the observation arm. The PFS was significantly improved for patients receiving alemtuzumab (P ¼ 0.036) at a median follow-up of 21.4 months. Collectively, these studies along with other noncontrolled reports (Moreton et al., 2005) provide support for this approach in the setting of a clinical trial. Off study, consolidation therapy with alemtuzumab is currently not supported by the available literature.
Alemtuzumab in autologous stem cell transplantation
As discussed previously, alemtuzumab is most effective in the absence of bulky nodal disease. The elimination of MRD is crucial for the outcome of CLL patients undergoing autologous hematopoietic stem cell transplantation (HSCT) due to concerns regarding graft contamination. At the same time, it is important that therapy not interfere with peripheral blood HSC mobilization and harvesting. The efficacy of alemtuzumab for the treatment of MRD Wendtner et al., 2004; Moreton et al., 2005; Montillo et al., 2006) and the absence of CD52 on hematopoietic stem cells (Gilleece and Dexter, 1993) support the rationale for in vivo purging with alemtuzumab before HSC collection. Dyer et al. (1997) was the first to report six CLL patients treated with purine analogs to maximal response followed by i.v. alemtuzumab for in vivo purging of residual disease after chemotherapy. Five patients achieved MRD-negative CRs with no detectable CD5 þ /CD19 þ cells by flow cytometry in the peripheral blood or bone marrow. Moreover, the authors showed that alemtuzumab did not affect stem cell collection, and stem cell products were not contaminated with CD5 þ /CD19 þ cells in three cases. This preliminary report was recently built upon by Montillo et al. (2006) , who treated 34 patients with sequential therapy including fludarabine-based regimens followed by s.c. alemtuzumab for 6 weeks. Overall, HSC collection after intermediate-dose cytarabine (800 mg/m 2 every 12 h for six doses) plus granulocyte-colony-stimulating factor was successful in 24 (92%) of 26 patients. Eighteen patients subsequently underwent HSCT after a median of 11 months from the end of alemtuzumab therapy, and 17 of these 18 patients were in CR at a median follow-up of 28 months after alemtuzumab therapy. The above study provides the first evidence demonstrating the feasibility of using alemtuzumab as consolidation and in vivo purging followed by autologous HSC collection and transplantation.
Alemtuzumab in allogeneic stem cell transplant for CLL Allogeneic HSCT is a potentially curative therapy for CLL (Michallet et al., 1996) , but its application has been limited to younger, healthy patients because of the potential toxicity of the procedure. Myeloablative allogeneic HSCT in CLL has a transplantation-related mortality (TRM) rate of approximately 50% (Flinn and Vogelsang, 1998; Hale et al., 2002) . Acute and chronic graft-versus-host disease (aGVHD, cGVHD) remain significant causes of morbidity and mortality. In recent years, reduced intensity conditioning regimens have been developed that are designed to be immunosuppressive rather than myeloablative (Sorror et al., 2005) .
Preliminary studies suggest that the addition of alemtuzumab to nonmyeloablative conditioning regimens may reduce the severity of GVHD, presumably through in vivo T-cell depletion (Kottaridis et al., 2000; Pe´rez-Simo´n et al., 2002; Faulkner et al., 2004; Delgado et al., 2006) . Kottaridis et al. (2000) treated 44 patients with lymphoid and myeloid malignancies using i.v. alemtuzumab in combination with a fludarabine-based nonmyeloablative conditioning regimen. The engraftment rate was 98% (42 of the 43 evaluable patients) and 33 of 43 evaluable patients (75%) were alive without evidence of progression/relapse after a limited follow-up of 9 months. Interestingly, the incidence of aGVHD was very low -only two patients (5%) developed grade II and no patients developed grade III-IV aGVHD. The authors also reported a low incidence of cGVHD, although this could not be fully assessed because of the short duration of follow-up at the time of publication. Pe´rez-Simo´n et al. (2002) retrospectively compared the results of two prospective trials carried out in the United Kingdom (Kottaridis et al., 2000) and Spain (Martino et al., 2001 ). The two groups used an identical fludarabine-based nonmyeloablative regimen but used different GVHD prophylaxis: Kottaridis et al. (2000) used i.v. alemtuzumab as part of the conditioning regimen at a dose of 20 mg/day on days À8 to À4 and Martino et al. (2001) used methotrexate. Both groups of patients received cyclosporine. The patients who received alemtuzumab had a significantly lower incidence of aGVHD that persisted even after donor lymphocytes infusion (DLI). The authors found no significant difference in terms of TRM rate between the two groups, but did note an association between development of aGVHD and disease response. Patients who received alemtuzumab required DLI to achieve a similar response rate when compared with those who received methotrexate. Furthermore, alemtuzumab significantly reduced the incidence of aGVHD incidence but was associated with a higher rate of CMV reactivation. A recent study (Delgado et al., 2006) reported results of an alemtuzumab-based reduced intensity regimen in 41 CLL patients. The engraftment rate was unexpectedly in the treatment of CLL L Alinari et al low (85%) when compared with those previously reported for NHL patients who received the same conditioning regimen (Morris et al., 2004) . Delgado et al. (2006) reported excellent results with a conditioning regimen consisting of alemtuzumab 20 mg/day on days À8 to À4 and combined with fludarabine and melphalan, with an ORR of 100% in chemosensitive patients and 86% in chemorefractory patients. These responses were durable in 74 and 43% of chemosensitive and chemorefractory patients, respectively. Acute GVHD was observed in 17 patients (41%), but only four patients (10%) developed grade III or IV aGVHD. Thirteen patients (33%) developed extensive cGVHD. The 2-year TRM rate was 26%, mostly due to infections. Only one study has compared alemtuzumab with other agents for in vivo T-cell depletion. Juliusson et al. (2006) found that patients who received alemtuzumab as part of the conditioning regimen initially had less initial toxicity with fewer fevers and lower transfusion requirements, the patients who received 30 mg/day for three consecutive days were more likely to have mixed chimerism post-transplant requiring DLI, and had more serious opportunistic infections which translated to greater non-relapse mortality. At the present time, the role of alemtuzumab in non-myeloablative stem cell transplant for CLL is uncertain.
Toxicity of alemtuzumab
Alemtuzumab is associated with predictable toxicities that may be prevented or abrogated, such as infusionrelated events and infectious complications. As the experience with alemtuzumab increases and larger numbers of patients are treated, previously unrecognized toxicities are being reported as summarized below.
Infusion-related events
The most common adverse events during alemtuzumab therapy are infusion-related, including rigors, fever, nausea, vomiting, skin rash, dyspnea and hypotension. These symptoms are a consequence of cytokine release (TNF-a, IFN-g IL-6 and IL10) likely derived from natural killer cells (Wing et al., 1996) . Such infusional events generally occur with the first dose, with significant variability in the severity of symptoms. In general, the intensity and frequency of infusional events usually decrease over the course of therapy. Systemic infusional events can be reduced by initial dose escalation and premedication with diphenhidramine and acetaminophen. Steroids (hydrocortisone) may be added in cases of prior severe adverse reactions (Osterborg et al., 2006) , and generally are effective. Infusional events may also be significantly reduced by SQ administration. SQ administration does induce a local injection site inflammatory reaction (erythema/edema) that in most patients is self-limited (Lundin et al., 2002; Hale et al., 2004) .
Hematologic and immunologic toxicity
The majority of CLL patients experience transient cytopenias during initial therapy with alemtuzumab, especially if pre-existing cytopenias are present or significant prior therapy has been administered. Thrombocytopenia is most common during the first 2 weeks of therapy and may necessitate platelet transfusion, particularly in patients with either pre-existing cytopenias or significant infusional toxicity. Neutropenia is most common during weeks 5 and 6 (Keating et al., 2002) . Grade IV neutropenia in the absence of infection or progressive disease is not an absolute contraindication to therapy. Prophylactic filgrastrim for neutropenia is not generally effective (Lin et al., 2005a) and may result in prolonged periods of neutropenia if administered for extended periods of time. Monocytes, natural killer cells and peripheral blood (but not tissue) antigen-presenting dendritic cells are also profoundly depleted by alemtuzumab (Buggins et al., 2002; Klangsinsirikul et al., 2002) . T-and B lymphocytes subpopulations are heavily depleted, with the nadir usually occurring between weeks 3 and 6 of therapy (Lundin et al., 2004) . These often do not recover until 1 year or greater after therapy (Keating et al., 2002) . The route of administration does not seem to affect the hematologic and immunologic activities of alemtuzumab. Autoimmune hemolytic anemia has been reported following alemtuzumab administration but the pathogenesis remains unclear.
Infectious complications with alemtuzumab
The stage of the disease, number of prior therapies and degree of underlying myelo-and immunosuppression increase the susceptibility to opportunistic and other severe infections irrespective of treatment with alemtuzumab (Perkins et al., 2002) . The incidence of infection appears to be augmented further by alemtuzumab. Rai et al. (2002) observed major infections in 10 (42%) of 24 pretreated CLL patients during alemtuzumab therapy. In the pivotal study by Keating et al. (2002) , 51 (55%) of the 93 pretreated CLL patients experienced one or more infections: septicemia occurred in 14 patients (15%), 11 experienced opportunistic infections, including seven CMV reactivations, six herpes simplex reactivations, four herpes zoster reactivations, two patients developed aspergillus pneumonia and one patient each developed Pneumocystis jiroveci (previously Pneumocystis carinii), rhinocerebral mucormycosis, systemic candidiasis, cryptococcal pneumonia and Listeria monocytogenes meningitis. Infections are usually observed during alemtuzumab treatment or within 30 days after completing therapy, and only occasionally seen after discontinuation of therapy (Lundin et al., 2004) . The most frequently observed opportunistic infection during alemtuzumab therapy is CMV reactivation, which is seen in between 15 and 25% of patients (Nguyen et al., 2002) . CMV reactivation is usually observed shortly after the T-cell nadir, between weeks 4 and 6 of therapy. Antiviral prophylaxis (acyclovir, famciclovir, valaciclovir) is effective for the prevention of herpes simplex and varicella zoster virus reactivation and is recommended in all patients receiving alemtuzumab. However, these agents do not prevent CMV reactivation. Fortunately, most cases of CMV reactivation respond rapidly to i.v. ganciclovir (Keating et al., 2002; Lundin et al., 2004) . A randomized study of prophylactic versus pre-emptive therapy with valgancyclovir (O'Brien et al., 2005) demonstrated CMV reactivation could virtually be eliminated by prophylaxis. Despite this single study, prophylactic treatment for CMV is controversial as is weekly monitoring for CMV antigenemia or viral DNA copy numbers. Our approach consists of weekly monitoring during therapy and for 2 months afterward, with pre-emptive treatment if evidence of CMV viremia is detected. Anti-Pneumocystis jiroveci prophylaxis is also recommended for these patients.
Cardiac toxicity with alemtuzumab
Controversial data exists concerning the possibility of cardiovascular toxicity with alemtuzumab (Keating et al., 2002; Ferrajoli et al., 2003; Lenihan et al., 2004) . Cardiac events, including arrhythmias and development of congestive heart failure, have been reported in both T-cell (Lenihan et al., 2004) and B-cell malignancies (Keating et al., 2002; Ferrajoli et al., 2003) . In the randomized phase III trial comparing alemtuzumab with chlorambucil as first-line therapy (Hillmen et al., 2006) , serious cardiac events were observed in four patients treated with alemtuzumab compared with no cardiac complications observed in the chlorambucil arm.
The possible mechanism of cardiac events with alemtuzumab remains unknown. CD52 is not expressed on the endothelial cell membrane, making direct injury to the coronary endothelial cells an unlikely explanation. It has been hypothesized that cardiac toxicity may be the result of cytokine release leading to coronary artery spasm (Lenihan et al., 2004) .
Sterility with alemtuzumab
Epithelial cells lining the epididymis, vas deferens and seminal vesicles strongly express the CD52 antigen (Hale et al., 1993) and shed it into seminal plasma, from where it can be transferred to other cells, particularly spermatozoa. Although alemtuzumab has been shown to agglutinate and inactivate sperm in vitro, to date no reproductive complications with systemic therapy have been reported, probably because alemtuzumab does not reach the seminal fluid in significant concentrations.
Conclusions
Alemtuzumab is a humanized monoclonal antibody that targets the pan-lymphocyte antigen CD52 and has demonstrated activity in CLL. Importantly, several recent studies have demonstrated that alemtuzumab is active against high-risk del(17p13.1) CLL which generally does not respond to other standard therapies in this setting. The widespread use of alemtuzumab has in part been limited by concerns regarding toxicity, including infusional events, myelosuppression and immune suppression. Recent data suggests that administration of SQ alemtuzumab may diminish serious infusional toxicity. In addition, a phase III study comparing alemtuzumab to chlorambucil as primary therapy found that fewer opportunistic infections occurred in patients treated with alemtuzumab, indicating that some infections observed in patients with CLL may in fact be related to underlying immune dysfunction related to the disease itself. Future studies with alemtuzumab should focus on efforts to better understand the mechanism of action of this antibody and the function of CD52 in both normal and transformed Tand B cells.
